
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
28 JUNE - Comprehensive List of Guidance Documents http://www.fda.gov/cder/guidance/guidlist.pdf
FDA has issued a Comprehensive List of Guidance Documents, available at:www.fda.gov/cder/guidance/guidlist.pdf






